NASDAQ · EQRXW
EQRx, Inc.
Healthcare · Biotechnology
$0.05
Up+$0.00 (+0.00%)
Updated Aug 25, 2026, 12:52 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.14B
- P/E ratio
- 5.4
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 16.5K
- Avg. volume
- 16.5K
Price performance
EQRXW price history
1M range · 0 trading sessions · Daily adjusted prices
EQRXW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest EQRXW news
The latest Smart Investors Daily articles mentioning EQRXW.
Stock researchCompany · Overview
EQRXW research
Overview
Company profile and research snapshot.
Company profile
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
